BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Brigatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Brigatinib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04223596-2024@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Brigatinib: Phase 2 readout est. (NCT04223596)
DESCRIPTION:Brigatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Clin
 ical Utility of Liquid Biopsy in Brigatinib ALK+ Patients\nEstimated prima
 ry completion: 30 November 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/brigatinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04223596
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04227028-2024@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:Brigatinib: Phase 1 readout est. (NCT04227028)
DESCRIPTION:Brigatinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Brig
 atinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advance
 d\, Metastatic\, or Recurrent NSCLC\nEstimated primary completion: 25 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/brigatinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042270
 28
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03707938-2024@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Brigatinib: Phase 1 readout est. (NCT03707938)
DESCRIPTION:Brigatinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Loca
 l Consolidative Therapy and Brigatinib in Treating Patients With Stage IV 
 or Recurrent Non-small Cell Lung Cancer\nEstimated primary completion: 28 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brigati
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03707938
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813079-2024@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Brigatinib: Phase 2 readout est. (NCT06813079)
DESCRIPTION:Brigatinib\, phase 2.\nStudy: Using Tumor Models to Determine T
 reatments\nEstimated primary completion: 17 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/brigatinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06813079
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04374305-2024@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Brigatinib: Phase 2 readout est. (NCT04374305)
DESCRIPTION:Brigatinib\, phase 2.\nStudy: Innovative Trial for Understandin
 g the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT
 -NF2)\nEstimated primary completion: 1 December 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/brigatinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04374305
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06620835-2024@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Brigatinib: Phase 2 readout est. (NCT06620835)
DESCRIPTION:Brigatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tria
 l for Local Ablative Treatment (LAT) Optimization in Patients With Advance
 d Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Ki
 nase (ALK) Rearrangement Treated by Brigatinib\nEstimated primary completi
 on: 1 October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 rigatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06620835
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04925609-2024@assetmemo.bio
DTSTAMP:20261121T005440Z
DTSTART;VALUE=DATE:20331231
DTEND;VALUE=DATE:20340101
SUMMARY:Brigatinib: Phase 1/2 readout est. (NCT04925609)
DESCRIPTION:Brigatinib\, phase 1/2.\nStudy: Brigatinib in Pediatric and You
 ng Adult Patients With ALK+ ALCL\, IMT or Other Solid Tumors\nEstimated pr
 imary completion: December 2033. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/brigatinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04925609
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
